Disclosure as attachment of the Nanoform 2022 Report of the Board of Directors and Financial Statements which were previously linked to a Company Release
Company release
Nanoform Finland Plc
October 25, 2024
16.15 Finnish time / 15.15 Swedish time
Disclosure as attachment of the Nanoform 2022 Report of the Board of Directors and Financial Statements which were previously linked to a Company Release
Nanoform Finland Plc reported February 28, 2023, FY2022 results with a Company Release including Financial Statements Review for January-December 2022.
In the Company Release the link to all additional documents were provided, including ‘Report of the Board of Directors and Financial Statements’, in English and Finnish.
The ‘Report of the Board of Directors and Financial Statements’, in English and Finnish, were not attached to the Company Release February 28, 2023. Nanoform hereby provides the documents as attachments to this release.
For further information please contact:
Henri von Haartman, Director of Investor Relations
+46 7686 650 11
About Nanoform
Nanoform is the medicine performance-enhancing company that leverages best-in-class innovative nanoparticle engineering technologies, expert formulation, and scalable GMP API manufacturing to enable superior medicines for patients. The company focuses on reducing clinical attrition and on enhancing drug molecules’ performance through its nanoforming technologies and formulation services, from pre-formulation to commercial scale. Nanoform will help improve bioavailability and drug delivery profiles, drive differentiation, patient adherence and extend the lifecycle potential of products. Nanoform’s shares are listed on the Premier-segment of Nasdaq First North Growth Market in Helsinki (ticker: NANOFH) and Stockholm (ticker: NANOFS). Certified Adviser: Carnegie Investment Bank AB (publ), +46 8-588 68 570. For more information, please visit www.nanoform.com.
